Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TOVX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTheriva reports VCN-01 improved survival in Phase 2b pancreatic cancer trial
Filed April 17, 2026 · Period ending April 17, 2026 · ~1 min read
Key Changes
-
high
VCN-01 combined with chemotherapy improved both overall survival and progression-free survival versus chemotherapy alone in metastatic pancreatic cancer patients. Late separation of survival curves suggests immune-mediated mechanism.
Item 7.01: VIRAGE Trial Results verify on EDGAR → -
high
Tumor responses with VCN-01 combination were later-emerging but stronger and more durable than chemotherapy alone, consistent with immunotherapy patterns and suggesting sustained clinical benefit.
Item 7.01: Treatment Response verify on EDGAR → -
medium
Patients receiving a second dose of VCN-01 showed greater survival benefit than single-dose patients, informing optimal dosing strategy for future trials and potential commercial use.
Item 7.01: Dosing Analysis verify on EDGAR → -
medium
Survival benefit maintained across patient subgroups including those with liver metastases, despite post-enrollment patient characteristic imbalances that could have skewed results.
Item 7.01: Subgroup Analysis verify on EDGAR → -
medium
Company presenting detailed VIRAGE trial data at AACR Annual Meeting on April 20, 2026, providing scientific peer review and visibility to oncology community.
Item 7.01: AACR Presentation verify on EDGAR →
Summary
Theriva Biologics disclosed positive Phase 2b clinical trial results for VCN-01, its experimental cancer therapy for metastatic pancreatic cancer. The VIRAGE trial showed that patients receiving VCN-01 plus standard chemotherapy lived longer and had delayed disease progression compared to chemotherapy alone.
Importantly, the survival benefit appeared late in treatment and responses were more durable, suggesting VCN-01 works by activating the immune system rather than directly killing tumors—a mechanism that could provide lasting benefit. For retail investors, this represents a significant clinical milestone for Theriva's lead asset.
Pancreatic cancer is notoriously difficult to treat, and any survival improvement is meaningful. The finding that a second dose produced better outcomes provides clear direction for future development. However, the company acknowledged patient characteristic imbalances after enrollment, which could affect data interpretation. Watch for peer and investor reaction to the full AACR poster presentation on April 20th. Key questions include the magnitude of survival improvement, safety profile, and whether these results support advancement to Phase 3 trials. Partnership interest from larger pharmaceutical companies could follow if the data holds up to scientific scrutiny.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Theriva Biologics disclosed clinical trial results for VCN-01 in metastatic pancreatic cancer via press release and poster presentation.
Added in current filing · verify on EDGAR →
Poster Presentation titled “Analysis of tumor and biomarker responses in the VIRAGE Trial, a randomized Phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)”
The company disclosed results from the VIRAGE Trial, a Phase IIb clinical study evaluating VCN-01 combined with standard chemotherapy (nab-paclitaxel and gemcitabine) versus chemotherapy alone in metastatic pancreatic cancer patients. The poster presentation analyzes tumor and biomarker responses, suggesting the company is sharing efficacy and biological activity data from this randomized trial. This represents a material clinical milestone for the company's lead oncology asset.
Added in current filing · verify on EDGAR →
Press Release issued by Theriva Biologics, Inc., dated April 17, 2026
The company issued a press release on the same date as the 8-K filing, likely providing additional context, commentary, or interpretation of the VIRAGE Trial data being presented. Press releases accompanying clinical data disclosures typically contain management's perspective on the results and potential implications for the development program.
Event · Item 7.01 — Regulation FD Disclosure
Theriva announced upcoming poster presentation of Phase 2b VIRAGE trial data for VCN-01 in metastatic pancreatic cancer at AACR meeting April 20, 2026.
Added in current filing · verify on EDGAR →
On April 17, 2026, Theriva Biologics, Inc. (the “Company”) issued a press release announcing an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients at the American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego, CA from 17-22 April 2026.
The company disclosed it will present new data and subgroup analyses from its VIRAGE Phase 2b clinical trial at the AACR Annual Meeting. The trial evaluates VCN-01 combined with gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients. The poster presentation is scheduled for Monday April 20, 2026, from 2:00-5:00 PM PDT.
Added in current filing · verify on EDGAR →
·Title: Analysis of tumor and biomarker responses in the VIRAGE Trial, a randomized Phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC) ·Poster #: CT162 ·Date and time: Monday April 20, 2026, 2:00-5:00 PM US PDT
The presentation will focus on tumor and biomarker responses from the randomized Phase IIb VIRAGE trial comparing treatment with and without intravenous VCN-01. Dr. Manuel Hidalgo from NYU Langone Health Perlmutter Cancer Center will be the presenting author. This is a Regulation FD disclosure providing advance notice of the data presentation.
Event · Item 8.01 — Other Events
Theriva announces upcoming AACR poster showing VCN-01 improved survival vs. chemo alone in Phase 2b pancreatic cancer trial.
Added in current filing · verify on EDGAR →
Patients receiving VCN-01 + gemcitabine/nab-paclitaxel (“GnP”) had improved overall survival and progressive free survival compared to GnP alone. The late separation of survival curves may reflect an immune-mediated mechanism of action.
The company disclosed that its experimental cancer therapy VCN-01, when combined with standard chemotherapy, improved both overall survival and progression-free survival compared to chemotherapy alone in metastatic pancreatic cancer patients. The delayed survival benefit suggests the drug may work through immune system activation rather than direct tumor killing.
Added in current filing · verify on EDGAR →
Treatment with VCN-01 + GnP resulted in later-emerging, higher magnitude, and more durable responses than GnP alone.
The combination therapy produced tumor responses that took longer to appear but were stronger and lasted longer than chemotherapy alone. This pattern is consistent with immunotherapy mechanisms and suggests potential for sustained clinical benefit beyond initial treatment.
Added in current filing · verify on EDGAR →
The OS benefit of VCN-01 + GnP was generally maintained across subgroups including liver metastases, despite a post-recruitment imbalance.
The survival benefit held up even in patients with liver metastases, a typically harder-to-treat subgroup. The company acknowledges there was an imbalance in patient characteristics discovered after enrollment, but the drug still showed benefit despite this statistical challenge.
Added in current filing · verify on EDGAR →
Patients receiving a second administration of VCN-01 revealed a greater benefit in OS and PFS.
Patients who received a second dose of VCN-01 had better survival outcomes than those receiving only one dose, suggesting repeat dosing may be important for maximizing therapeutic benefit and informing optimal treatment protocols for future trials.
Added in current filing · verify on EDGAR →
On April 17, 2026, the Company issued a press release announcing an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients at the American Association for Cancer Research (AACR) Annual Meeting to be held in San Diego, CA from 17-22 April 2026.
The company is presenting detailed trial results at a major cancer research conference (AACR) on April 20, 2026. This provides scientific visibility and peer review of the data, which can influence clinical adoption and partnership opportunities.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify